The purpose of this study is to evaluate a potential long-acting injectable HIV treatment option for people whose HIV is not undetectable.

The study drug is a long-acting HIV treatment. It is given by injection every other month after 2 started doses. This is in contrast to oral ART, which is designed to be taken daily.

Participants are randomized to one of two groups. Randomization is like pulling names out of a hat to decide who goes into which group, making sure the selection is fair and unpredictable. There is a 3-in-4 chance of being in Group 1 and a 1-in-4 chance of being in Group 2.

Group 1: Study drug injections once every 2 months after 2 once-monthly started doses

OR

Group 2: Oral ART for 6 months followed by study drug injections once every 2 months after 2 once-monthly starter doses (if HIV is undetectable at month 6). 

The study will last for about 2 years. This will include up to 20 scheduled study visits.